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Original Article
A randomized prospective long-term
(>1 year) clinical trial comparing the
efficacy and safety of radiofrequency
ablation to 980nm laser ablation of
the great saphenous vein
Malcolm Sydnor1, John Mavropoulos2, Natalia Slobodnik1,
Luke Wolfe3, Brian Strife1 and Daniel Komorowski1
Abstract
Purpose: To compare the short- and long-term (>1 year) efficacy and safety of radiofrequency ablation
(ClosureFASTTM) versus endovenous laser ablation (980 nm diode laser) for the treatment of superficial venous insuf-
ficiency of the great saphenous vein.
Materials and methods: Two hundred patients with superficial venous insufficiency of the great saphenous vein were
randomized to receive either radiofrequency ablation or endovenous laser ablation (and simultaneous adjunctive thera-
pies for surface varicosities when appropriate). Post-treatment sonographic and clinical assessment was conducted at
one week, six weeks, and six months for closure, complications, and patient satisfaction. Clinical assessment of each
patient was conducted at one year and then at yearly intervals for patient satisfaction.
Results: Post-procedure pain (p< 0.0001) and objective post-procedure bruising (p¼ 0.0114) were significantly lower
in the radiofrequency ablation group. Improvements in venous clinical severity score were noted through six months in
both groups (endovenous laser ablation 6.6 to 1; radiofrequency ablation 6.2 to 1) with no significant difference in venous
clinical severity score (p¼ 0.4066) or measured adverse effects; 89 endovenous laser ablation and 87 radiofrequency
patients were interviewed at least 12 months out with a mean long-term follow-up of 44 and 42 months (p¼ 0.1096),
respectively. There were four treatment failures in each group, and every case was correctable with further treatment.
Overall, there were no significant differences with regard to patient satisfaction between radiofrequency ablation and
endovenous laser ablation (p¼ 0.3009). There were no cases of deep venous thrombosis in either group at any time
during this study.
Conclusions: Radiofrequency ablation and endovenous laser ablation are highly effective and safe from both anatomic
and clinical standpoints over a multi-year period and neither modality achieved superiority over the other.
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Introduction
Chronic venous insuﬃciency (CVI) is the most preva-
lent vascular disease in the United States with an esti-
mated 25 million Americans aﬀected by this debilitating
condition.1 Symptoms of CVI include cramping, pain,
early fatigue, throbbing, and itching while physical
ﬁndings include varicose veins, dyspigmentation of
the skin, edema, eczema, lipodermatosclerosis, and
ulceration. The primary cause of CVI is thought to be
poorly functioning venous valves, nearly always at the
lower limbs, resulting in prolonged retrograde ﬂow of
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deoxygenated blood. Of the superﬁcial veins in the
lower extremity, the great saphenous vein (GSV) is
the most common cause of CVI in symptomatic
patients.2,3
The treatment of CVI has undergone a revolution
with the introduction of endovenous thermal ablation
(EVTA) as the most preferred method over high surgical
ligation and stripping. EVTA is a catheter-based tech-
nique utilizing electromagnetic (EM) energy to obliterate
the GSV in a minimally invasive, oﬃce-based procedure.
Indeed, whereas surgical ligation and stripping requires
general anesthesia and a prolonged recovery period,4
EVTA can be performed in an outpatient setting
allowing patients to resume normal daily activities with
minimal delay. In addition, numerous studies have
demonstrated EVTA to have at least equal, and often
greater, eﬃcacy than surgical ligation and stripping for
the treatment of CVI.5–9
The increasing popularity of EVTA has spurred the
generation of an array of devices in this rapidly growing
arena in phlebology. Variations in devices primarily
revolve around ﬁber tip design and type of EM
energy utilized to ablate a vein, the latter of which
can be dichotomized into either non-laser radiofre-
quency (RF) emitting devices or laser-based devices
emitting near- to short-wavelength infrared light
(810–1500 nm). While initial EVTA procedures were
performed with RF devices (denoted as RF ablation,
RFA), an abundance of laser devices soon followed,
with each device emitting a wavelength primarily tar-
geting either hemoglobin (810, 940, 980, and 1064 nm)
or water (1320, 1470, and 1500 nm) as a principle
chromophore. The importance of wavelength selection
for endovenous laser ablation (EVLA), however, has
been called into question as higher power settings,
faster catheter pullback velocities, and vein diameter
at time of treatment irrespective of wavelength are
thought to be the primary determinants for the success-
ful treatment of CVI.10,11
During the past decade, numerous studies have inde-
pendently conﬁrmed the eﬀectiveness of RFA and
EVLA. In particular, clinical studies utilizing RFA
reveal excellent short- and long-term results with
4%–17% recanalization rates up to four years after
treatment.6,7,9,16–18 Similarly, EVLA exhibits 0%–10%
recanalization rates for up to one year after treat-
ment.5,14,16–18 Such studies also demonstrate impressive
safety proﬁles for both techniques with a deep venous
thrombosis (DVT) rate of 1% in all but one study13
and only two pulmonary emboli in over 2500 treated
limbs. Minor complications such as skin burns, pares-
thesias, and phlebitis occur more often with RFA,
whereas EVLA is associated with a greater number of
vein perforations,19 post-procedure bruising, and asso-
ciated pain.17
In light of these results, manufacturers of RF devices
have aggressively marketed the advantages of less
bruising and pain as a basis to prefer RFA over
EVLA20 and, indeed, more recent, albeit small, studies
support these claims.21–26 Yet, despite this mounting
body of evidence, there is little data directly comparing
RFA and EVLA in a long-term (>1 year) setting. We
therefore conducted a prospective randomized single-
blinded study to directly compare RFA to EVLA
with regards to immediate subjective and objective
post-procedure bruising (OPPB) and pain as well as
short- and long-term (>1 year) eﬃcacy and complica-
tions. It is our hope that the present study will contrib-
ute to the existing evidence regarding comparative
outcomes between RFA and EVLA in order to assist
physicians and patients in choosing the most appropri-
ate modality for the treatment of CVI.
Methods
Patient population
This study was approved by the Institutional Review
Board and conducted in accordance with the principles
of the Declaration of Helsinki (October 1996 version).
Informed consent was obtained from every patient and
enrollment occurred from September 2008 through
February 2012. Eligible subjects were new patients
with symptoms of CVI who underwent a color ﬂow
duplex ultrasound examination with a high-resolution
linear probe (7 to 12 MHz). All patients were given the
opportunity to be included in the study if they satisﬁed
the following criteria: (1) CVI symptoms caused by
GSV reﬂux, deﬁned as reverse ﬂow in the GSV greater
than 0.5 s after calf compression in the standing pos-
ition, (2) a clinical-etiology-anatomy-pathophysiology
(CEAP) clinical class of 2 or greater, and (3) prior
attempt of at least six weeks of compression stockings
for conservative management of CVI. Of note, treat-
ment of CVI with compression stockings was not
required if a patient exhibited venous ulcers or bleeding
varices.
Exclusion criteria for this study included: (1) previ-
ous vein surgery, EVTA, or phlebectomy in the target
extremity (excluding sclerosant injections for spider
veins or other superﬁcial cosmetic procedures),
(2) active or prior DVT in the target extremity, (3)
active or prior hypercoagulability disorder, (4) patients
who are pregnant or breastfeeding, (5) patients who are
non-ambulatory, (6) age less than 18 years, and (7)
patients who are prisoners. All patients satisfying
these criteria were given the opportunity to enroll in
the study prior to undergoing an EVTA procedure. In
total, two hundred patients were prospectively enrolled
in this trial. All patient charts with photographs
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remained in a locked oﬃce, and the patient database
was kept in a secure password protected format.
Upon inclusion into the study, each participating
patient was randomized into either the ‘‘LASER
Group’’ (EVLA) or the ‘‘RF Group’’ (RFA) and
underwent an EVTA procedure within six months
from the time of enrollment. Randomization was per-
formed in blocks of two, four, or six patients in order
prevent ascertainment of allocations as well as to assure
identical sizes of overall treatment groups. The follow-
ing variables were collected for each patient after ran-
domization: location of target vein (right or left GSV),
gender, race, age, height, weight, body mass index,
symptom duration, initial CEAP class, initial venous
clinical severity score (VCSS), number of pregnancies,
immediate family history of symptomatic varicose
veins, and presence or absence of reﬂux in other saphe-
nous veins (including ipsilateral or contralateral small
saphenous vein, contralateral GSV, or ipsilateral-
duplicated GSV).
EVTA procedures
Patients were blinded with regard to undergoing either
EVLA or RFA. The majority of cases were performed
in an oﬃce setting without conscious sedation (CS),
although CS was commonly administered when
adjunctive ambulatory phlebectomy (AP) was per-
formed. Patients were prepped and draped in a sterile
manner, and all procedures were performed by one of
two attending Interventional Radiologists.
Detailed step-by-step summaries of the procedural
aspects of RFA and EVLA of the GSV have been
reviewed previously27 and will not be discussed exten-
sively. In this study, both techniques are nearly identi-
cal with regard to accessing the GSV, injecting
tumescent anesthesia, and placement of the catheter
tip 1 to 2 cm distal to the saphenofemoral junction
(SFJ) under ultrasound guidance prior to initiating
EVTA treatment.
Brieﬂy, EVLA was performed as follows: the GSV
was accessed from a point immediately below the knee
or higher as permitted by the patient’s venous anatomy,
and the LASER tip was positioned 1 to 2 cm distal to
the SFJ under ultrasound guidance. Tumescent anes-
thesia (500 cc normal saline mixed with 40 cc of 1%
lidocaine with epinephrine and 4 cc of sodium bicar-
bonate) was injected liberally in a distal to proximal
direction within the saphenous space along the targeted
segment of the GSV. Thermal energy was delivered
using a 980 nm diode laser system (Angiodynamics,
Queensbury, NY) at a ﬂuence range of 50 to 80 J/cm
and a power setting of 10 W with a constant continu-
ous pullback velocity. Patients with symptomatic
surface varicosities were also oﬀered AP and/or
ultrasound-guided foam sclerotherapy (USGFS) as an
adjunctive component of the original procedure. After
the procedure was completed, steri-strips, sterile dres-
sing, and compression stockings were applied, the latter
worn continuously for the ﬁrst 24 h and then during
daytime hours for the next 14 consecutive days.
Periprocedural data were immediately recorded includ-
ing total treatment time (TTT), total tumescent volume,
catheter length required, total ablation time (TAT),
adjunctive procedures as needed, the use of CS if neces-
sary, and complications.
RFA procedures were performed in an identical
manner with regard to vein access, catheter tip pos-
itioning, and injection of tumescent anesthesia.
Heat energy (120C) was then delivered segmentally
in discrete 20-s cycles spaced 6.5 cm apart via
VNUS ClosureFASTTM technology (VNUS Medical
Technologies Inc, Sunnyvale, CA). Of note, two con-
secutive 20-s cycles were applied at the starting point
1 to 2 cm distal to the SFJ, and all other segments were
treated with one cycle. Adjunctive treatments were
oﬀered, and identical peri- and post-procedure proto-
cols were followed as described for EVLA previously.
Follow-up
All patients were evaluated post-operatively by inter-
view, physical examination, photographs, and ultra-
sound examination as per protocol. Every eﬀort was
made to conduct this evaluation during the ﬁrst seven
days post-operatively although, in rare cases, this was
not possible. During this evaluation, the procedure was
judged a primary technical success if ultrasound exam-
ination revealed closure of the GSV with no new reﬂux,
neovascularity, or other reﬂuxing truncal veins arising
from or near the SFJ and no more than a 2 cm area of
patent vein below the SFJ. The following data were
collected during this visit (of note, all data recorded
on a 10-point scale followed the same graded format:
1¼ no sign or symptom and 10¼worst severity of sign
or symptom.): post-operative day (POD) of initial
evaluation, primary vein closure (yes or no), DVT
(yes or no), pain during procedure (1 to 10), post-
procedural pain (PPP) during the initial evaluation
(1 to 10), subjective post-procedure bruising (1 to 10),
OPPB (1 to 10), objective deep ecchymosis/hematoma
(yes or no), paresthesia (yes or no), new spider veins
(yes or no), thermal injury (yes or no), and overall sat-
isfaction (yes or no). Objective data were interpreted
and recorded by a nurse practitioner blinded with
regard to the speciﬁc EVTA procedure (EVLA or
RFA) performed on each patient.
Following the initial post-procedural visit, patients
were re-evaluated at six weeks and again at six months
after EVTA to further undergo an interview, physical
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examination and ultrasound examination as per proto-
col. During these visits, the following data were col-
lected: POD number, VCSS, sonographic evidence of
GSV closure (yes or no), sonographic evidence of neo-
vascularity (yes or no), sonographic evidence of DVT
(yes or no), post-procedural infection (yes or no), par-
esthesia (yes or no), phlebitis (yes or no), presence of
recurrent symptoms (yes or no), persistent pain or ten-
derness at the operative site (yes or no), physical evi-
dence of new spider veins at the operative site (yes or
no), physical evidence of hyperpigmentation/erythema
(H/E) (yes or no), and physical evidence of cutaneous
thermal injury (yes or no). Patients were also asked if
they were satisﬁed with the procedure in terms of reso-
lution of their initial concerns/symptoms (yes or no)
and to rate their overall satisfaction with the EVTA
procedure on a scale of 1 (completely dissatisﬁed) to
10 (completely satisﬁed).
Patients were subsequently contacted via phone at
yearly intervals and asked if they were satisﬁed with
the EVTA procedure in terms of resolution of their
initial concerns/symptoms (yes or no). If the patient
answered ‘‘no,’’ then he/she was oﬀered further evalu-
ation with a clinic visit, sonographic evaluation, and
adjunctive treatment as needed. Based on their satisfac-
tion regarding resolution of their original complaints,
patients were ultimately categorized into one of three
following groups from data obtained during the last
recorded follow-up: (1) not requiring additional treat-
ments and ultimately satisﬁed, or (2) requiring further
adjunctive treatments and ultimately satisﬁed, or
(3) not satisﬁed.
Results
Pre-procedure data
EVLA and RFA groups were compared in terms of
basic demographic information, VCSS, and CEAP
scores. Initial descriptive statistics of patients from
both groups can be found in Table 1. Medians for
continuous variables were compared using the non-
parametric Wilcoxon rank-sum (Mann–Whitney U)
test, and proportions were compared using Fisher’s
exact test. No statistically signiﬁcant diﬀerences were
found between groups.
EVTA procedure
Table 2 compares procedural data between groups.
Variables were compared using the Wilcoxon rank-
sum or Fisher’s exact test. Statistically signiﬁcant
diﬀerences between groups included longer required
catheter length and shorter TAT in the RFA group.
However, there was no statistically signiﬁcant diﬀer-
ence in TTT, total tumescence volume, the use of
Table 1. Demographic comparisons.
EVLA (n¼ 100) RFA (n¼ 100) p value
Age (years) (median (range)) 48.5 (23–86) 47 (19–86) 0.5476a
BMI (kg/m2) (median (range)) 27.3 (18.3–45.6) 27.9 (19.0–44.7) 0.9441a
Number of pregnancies (median (range)) 2 (0–9) 2 (0–8) 0.7600a
Symptom duration (months) (median (range)) 98 (4–480) 67 (2–444) 0.2009a
Initial CEAP clinical class (median (range)) 3 (2–11) 2 (2–8) 0.2095a
Initial VCSS (median (range)) 5 (2–26) 5 (1–20) 0.7463a
Right leg vein involvement 53% 47% 0.4796b
Female gender 77% 80% 0.7310b
Race/ethnicity 0.5357b
Caucasian 70% 78%
African American 18% 16%
Hispanic 7% 3%
Asian 3% 1%
Other 2% 2%
Immediate family history of saphenous reflux 70% 71% 1.0000b
Reflux in other saphenous veins 57% 58% 1.0000b
EVLA: endovenous laser ablation; RFA: radiofrequency ablation; BMI: body-mass index; CEAP: clinical-etiology-anatomy-pathophysiol-
ogy; VCSS: venous clinical severity score.
aWilcoxon rank-sum test.
bFisher’s Exact test.
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adjunctive treatments for surface varicosities, or the use
of CS between groups. There were no peri-procedural
complications in either group.
Initial post-procedural evaluation
One-hundred patients in each group completed an ini-
tial post-procedural evaluation. All saphenous veins
were closed, and there was no sonographic evidence
of DVT or endovenous heat-induced thrombosis in
either group. Table 3 compares initial post-procedural
outcomes between groups. Overall, PPP (p< 0.0001)
and OPPB (p¼ 0.0114) were signiﬁcantly lower in the
RFA group, by a median diﬀerence of 3 and 1,
respectively.
Six-week post-procedural evaluation
Table 4 compares the subjective and objective data
between groups at the six-week post-procedural
evaluation. Overall, 96 and 97 patients completed a
six-week post-procedural evaluation in the EVLA and
RFA groups, respectively. Sonographic evaluation
revealed two cases of partial GSV recanalization in
the EVLA group and one case of partial GSV recana-
lization in the RFA group. There were no cases of
DVT. There were no signiﬁcant diﬀerences in minor
complications between groups.
Six-month post-procedural evaluation
Table 5 compares the subjective and objective data
between groups at a six-month post-procedural evalu-
ation. Overall, 79 and 74 patients completed a full
six-month post-procedural evaluation with ultra-
sound in the EVLA and RFA groups, respectively.
Sonographic evaluation revealed two additional cases
of truncal superﬁcial reﬂux in the RFA group (partial
GSV recanalization in one patient and central GSV
recanalization supplying a new reﬂuxing anterior
Table 3. Initial post-procedural outcomes.
EVLA (n¼ 100) RFA (n¼ 100) p value
Post-operative day of initial evaluation (median (range)) 5 (1–29) 6 (1–9) 0.1922a
Pain during procedure (scale 1–10) (median (range)) 4 (1–10) 3 (1–10) 0.1163a
Post-procedural pain (scale 1–10) (median (range)) 5 (1–10) 2 (1–10) <0.0001a
Subjective post-procedural bruising (scale 1–10) (median (range)) 3 (1–10) 3 (1–8) 0.0847a
Objective post-procedural bruising (scale 1–10) (median (range)) 3 (1–8) 2 (1–9) 0.0114a
Objective deep ecchymosis/hematoma 5% 2% 0.4448b
Paresthesia 16% 23% 0.2842b
New spider veins 1% 1% 1.0000b
Thermal injury 0% 0% –
Satisfaction 93% 92% 1.0000b
EVLA: endovenous laser ablation; RFA: radiofrequency ablation.
aWilcoxon rank-sum test.
bFisher’s exact test.
Table 2. Procedural Data.
EVLA (n¼ 100) RFA (n¼ 100) p value
Total treatment time (minutes per case) (median (range)) 23.5 (8–95) 21 (6–64) 0.1772a
Total tumescence volume (mL per case) (median (range)) 450 (50–800) 475 (100–850) 0.2578a
Catheter length required (cm per case) (median (range)) 31 (11–52) 37 (9–69) <0.0001a
Total ablation time (minutes per case) (median (range)) 5 (1–18) 4 (1–14) 0.0009a
Ambulatory phlebectomy or ultrasound-guided foam sclerotherapy 53% 45% 0.3221b
Patients requiring conscious sedation 16% 15% 1.0000b
Procedural complications 0% 0% –
EVLA: endovenous laser ablation; RFA: radiofrequency ablation.
aWilcoxon rank-sum test.
bFisher’s Exact test.
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tributary pathway in another patient) and no cases of
reﬂux in the EVLA group. There were no cases of DVT
in either group. There were no signiﬁcant diﬀerences in
minor complications. Improvements in VCSS were
noted over time in both groups. There was no signiﬁ-
cant diﬀerence in median VCSS between groups at the
initial, six-week, or six-month follow-up time points
(p¼ 0.7705 by repeated measures analysis of variance
analysis with a Bonferroni adjustment).
Technical long-term follow-up
During the long-term follow-up period (>1 year), 17
(19.1%) patients from the EVLA group and 10
(11.5%) patients from the RFA group (p¼ 0.2099
Fisher’s Exact Test) underwent additional ultrasound
examinations for concerning clinical ﬁndings. Of these
patients, recurrent truncal reﬂux originating from a
recanalized central GSV at the SFJ supplying a new
reﬂuxing anterior tributary pathway was noted in two
patients from the EVLA group (at 28 months and
33 months). One patient from the RFA group had a
recurrent reﬂuxing GSV at 35 months.
Overall, throughout all time points evaluated in this
study, there were a total of four distinct patients in each
group with sonographically conﬁrmed recurrent truncal
reﬂux originating at the SFJ (eight total cases of recur-
rent reﬂux—see Table 6). Primary assisted closure was
achieved for 100% of these patients after additional
treatments. There were no DVTs or other major com-
plications identiﬁed in any patient throughout the
entire study period.
Univariate analysis reveals subjects with recurrent
reﬂux (n¼ 8) were younger on average than the remain-
ing subjects (n¼ 192) (32.0 years [range: 19–66] vs.
48.5 years [range: 23–86], respectively; Wicoxon
rank-sum test). Step-wise logistic regression reveals
decreasing age and increasing symptom duration as
statistically signiﬁcant predictors of failure.
Clinical long-term follow-up
Of the 100 patients in each group, 89 EVLA patients
and 87 RFA patients were interviewed at least
12 months after EVTA. The mean long-term follow-
up in the EVLA group was 44 (12–64) months, and
the mean long-term follow-up in the RFA group was
42 (12–75) months (p¼ 0.1096 Wilcoxon rank-sum
test). Sixty-nine patients in each group (77.5% EVLA
and 79.3% RFA) were satisﬁed with the treatment
results and did not require further evaluation or treat-
ment (Group 1). Fifteen patients in the EVLA group
Table 4. Six-week follow-up evaluation.
EVLA (n¼ 96) RFA (n¼ 97) p value
Post-operative day (median (range)) 47.5 (28–311) 43 (23–520) 0.2854a
VCSS (median (range)) 2 (0–8) 2 (0–15) 0.9734a
Patient satisfaction (scale 1–10) (median (range)) 9 (5–10) 9 (1–10) 0.3983a
Neovascularization 0% 0% –
AP or USGF (number administered post-procedurally) 0.1806b
0 62.50% 50%
1 32.29% 44.79%
2 4.17% 5.21%
3 1.04% 0%
Infection 3.13% 2.08% 1.0000b
New spider veins 7.29% 3.13% 0.3306b
Thermal injury 0% 0% –
Great saphenous vein closure 97.92% 98.96% 1.0000b
Deep venous thrombosis 0% 0% –
Recurrent symptoms 5.21% 6.19% 1.0000b
Persistent pain or tenderness at operative site 17.71% 18.56% 1.0000b
Phlebitis 1.04% 1.03% 1.0000b
Hyperpigmentation/erythema 3.16% 3.13% 1.0000b
Paresthesia 9.38% 13.68% 0.3744b
EVLA: endovenous laser ablation; RFA: radiofrequency ablation; VCSS: venous clinical severity score; AP: ambulatory phlebectomy;
USGF: ultrasound-guided foam sclerotherapy.
aWilcoxon rank-sum test.
bFisher’s exact test.
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(16.9%) and nine patients in the RFA group (10.3%)
were ultimately satisﬁed but required additional
adjunctive treatments after the ﬁrst six weeks (Group
2). Finally, ﬁve patients in the EVLA group (5.6%) and
nine patients in the RFA group (10.3%) reported at last
follow-up that they were not happy with the treatment
results relative to their original complaints (Group 3).
Overall, there were no signiﬁcant diﬀerences with
regard to patient satisfaction between RFA and
EVLA (p¼ 0.3009).
Discussion
This prospective randomized single-blinded compari-
son trial between EVLA and RFA demonstrates both
modalities are highly eﬀective from both anatomical
and clinical standpoints. In both treatment groups,
EVTA was highly successful from both a technical
standpoint (96% primary GSV closure and 100% pri-
mary assisted closure in each group) and in terms of
safety (no cases of DVT in either group) to treat GSV-
mediated CVI. Clinically, nearly 80% of patients in
both groups who had long-term follow-up were satis-
ﬁed with their results without requiring adjunctive
treatments beyond the ﬁrst six weeks.
While there was increased immediate post-operative
pain and bruising for EVLA relative to RFA, there was
no diﬀerence in patient satisfaction parameters between
modalities at any of the subsequent pre-speciﬁed time
points in our study, and both groups demonstrated a
substantial reduction in VCSS through six months.
Table 5. Six-month follow-up evaluation.
EVLA (n¼ 79) RFA (n¼ 74) p value
Post-operative day (median (range)) 188.5 (99–330) 187.5 (129–352) 0.6945a
VCSS (median (range)) 1 (0–18) 1 (0–6) 0.3338a
Patient satisfaction (score 1–10) (median (range)) 9 (4–10) 9 (1–10) 0.6698a
Neovascularization 0% 0% –
AP or UGFS (number administered post-procedurally) 0.5485b
0 44.30% 44.59%
1 43.04% 48.65%
2 7.59% 6.76%
3 2.53% 0%
4 2.53% 0%
Infection 0% 0% –
New spider veins 15.19% 13.51% 0.8207b
Thermal injury 0% 0% –
Great saphenous vein closure 98.73% 97.30% 0.6105b
Deep vein thrombosis 0% 0% –
Recurrent symptoms 7.59% 6.76% 1.0000b
Persistent pain or tenderness at operative site 11.39% 13.51% 0.8076b
Phlebitis 0% 2.70% 0.2323b
Hyperpigmentation/erythema 12.66% 8.11% 0.4334b
Paresthesia 10.26% 8.33% 0.7827b
EVLA: endovenous laser ablation; RFA: radiofrequency ablation; VCSS: venous clinical severity score; AP: ambulatory phlebectomy;
USGF: ultrasound-guided foam sclerotherapy.
aWilcoxon rank-sum test.
bFisher’s exact test.
Table 6. Primary treatment failures.
Treatment
group
Time
identified New reflux Treatment Final result
EVLA Six weeks GSV EVLA Vein closure
EVLA Six weeks Partial GSV USGFS Vein closure
EVLA 28 months Central GSV USGFS Vein closure
EVLA 33 months Central GSV EVLA Vein closure
RFA Six weeks Partial GSV USGFS Vein closure
RFA Six months Partial GSV USGFS Vein closure
RFA Six months Central GSV RFA Vein closure
RFA 35 months GSV RFA Vein closure
EVLA: endovenous laser ablation; GSV: great saphenous vein; RFA: radio-
frequency ablation; USGFS: ultrasound-guided foam sclerotherapy; partial
GSV: partial GSV recannulization; central GSV: proximal GSV supplying a
new refluxing anterior tributary.
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When our study was initiated, there were no pro-
spective randomized comparisons between EVLA and
RFA. Since that time, several studies have been
published directly comparing EVLA and RFA for
GSV-mediated CVI. The ﬁrst single-blinded study
(the RECOVERY trial) was published by Almeida
et al.21 involving 46 veins treated with ClosureFastTM
RFA and 41 veins treated with EVLA (980 nm).
Patients were followed for one month, and they found
that RFA led to reduced post-operative pain, tender-
ness, and ecchymosis at 48 h, one week, and two weeks.
RFA also led to a reduced incidence of phlebitis at
48 h, and VCSS and quality-of-life (QOL) measures
improved for RFA relative to EVLA at 48 h, one
week, and two weeks. Major complications did not
occur with either modality.
Similar results were reported in a slightly larger
single-blinded study by Shepherd et al.26 comparing
64 EVLA (980 nm) and 67 RFA (VNUS
ClosureFastTM) patients over a six week period.
Median pain scores were signiﬁcantly lower for RFA
patients at 3- and 10-days post-procedurally although
both modalities had similar outcomes in terms of clin-
ical and QOL improvements at six weeks.
Gale et al.22 conducted a comparative study in 118
patients and reported RFA and EVLA (810 nm) groups
had similar perioperative results. However, at one year,
GSV closure failure occurred in 11 out of 46 RFA
patients and in only 2 of 48 EVLA patients. Of note,
unlike Almeida et al., Gale utilized an older version of
RFA technology requiring continuous pullback of the
catheter. This technology was subsequently replaced in
2007 after demonstration of inferiority23 relative to seg-
mental pullback RFA technology commonly used by
other investigators and in our study. Therefore, the
conclusion by Gale et al. that LASER ‘‘may provide
a more secure closure over the long-term than RFA’’
must be interpreted with caution.
Nordon et al.25 compared 80 EVLA (810 nm) and
79 RFA (VNUS ClosureFastTM) patients and
demonstrated nearly identical GSV occlusion rates at
three-months for both modalities (96% and 97%,
respectively). Post-operative pain and bruising within
the ﬁrst week of treatment was worse for EVLA
although improvements in QOL were statistically simi-
lar for both modalities at three months.
In the largest similar study to date, Rasmussen
et al.28 recruited 500 patients to compare EVLA (980
or 1470 nm bare tip ﬁbers), RFA (VNUS
ClosureFastTM), surgical stripping, and USGFS (125
patients per group) and reported one-year failure
rates (i.e., return of GSV reﬂux) of 5.8%, 4.8%,
4.8%, and 16.3%, respectively. RFA was associated
with the least pain throughout the ﬁrst 10-days
post-procedurally followed by USGFS, surgery, and
lastly, EVLA. Of note, greater than 80% of patients
in the EVLA group were treated with the 1470 nm
device. In addition, RFA and USGFS were associated
with the shortest time for patients to resume to normal
daily activities and return to work. Overall, all four
treatment modalities led to comparable improvements
in QOL at one year after treatment.
Prior to our study, the longest direct-comparison
trials of EVLA and RFA were conducted over a one-
year timeframe. The present study was performed in a
randomized controlled prospective single-blinded fash-
ion with a patient population of 200 over a multi-year
period. Consistent with studies mentioned previously,
we observed RFA leads to less PPP and bruising rela-
tive to EVLA (980 nm bare tip laser). There was no
diﬀerence in these modalities at six weeks after treat-
ment and both remained eﬀective after three-and-a-half
years.
The use of bare tip lower wavelength LASER ﬁbers
is a potential drawback for this study. At the time of
study initiation, only bare-tipped ﬁbers were in use, and
thereafter, the development of jacketed ﬁbers has been
marketed as a means to prevent direct contact of the
vein wall with the energy emitting tip, which may
decrease the risk of vein perforation among other com-
plications. To date studies have shown a decrease in
immediate PPP with jacketed LASER ﬁbers relative
to bare-tipped ﬁbers,29 and a pilot study comparing
RFA (ClosureFastTTM) to EVLA (980 nm jacket-
tipped ﬁber) demonstrated no diﬀerence in pain and
bruising scores at one week after ablation.30,31 While
promising, these results must be replicated in larger
studies.
Overall, this prospective randomized study demon-
strates that both EVTA modalities can be technically
successful with no major complications over a period of
years. Perhaps more importantly, this study demon-
strates that both modalities result in high clinical satis-
faction at three-and-a-half year follow-up. As these
technologies continue to improve and new technologies
including non-tumescent ablation continue to emerge,
further longitudinal direct-comparison studies will be
needed.
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